Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: Correlation of clinical phenotype with flow-based platelet adhesion

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1409-1416

  McKinnon, T A J ^a   Nowak, A A ^a   Cutler, J ^b   Riddell, A F ^c   Laffan, M A ^a   Millar, C M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Flow assays; Platelet binding function; Von Willebrand disease; Von Willebrand factor

Indexed keywords

COLLAGEN; GLYCOPROTEIN IB ALPHA; RECOMBINANT VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLEEDING; CELL STRAIN HEK293; ELECTROPHORESIS; FEMALE; HUMAN; HUMAN TISSUE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE; WILD TYPE;

BLOOD PLATELETS; CELL ADHESION; FEMALE; HEK293 CELLS; HUMANS; MALE; MUTATION; PEDIGREE; PHENOTYPE; VON WILLEBRAND FACTOR;

EID: 84863438092     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04760.x     Document Type: Article

References (17)

1. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
2. Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 2062-6.
3. Riddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, Sutherland M, Laffan MA, McKinnon TA. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009; 114: 3489-96.
4. Millar CM, Riddell AF, Brown SA, Starke R, Mackie I, Bowen DJ, Jenkins PV, van Mourik JA. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost 2008; 99: 916-24.
5. Celikel R, Varughese KI, Madhusudan, Yoshioka A, Ware J, Ruggeri ZM. Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nat Struct Biol 1998; 5: 189-94.
6. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 2008; 111: 3042-9.
7. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-13.
8. Zwaginga JJ, Nash G, King MR, Heemskerk JW, Frojmovic M, Hoylaerts MF, Sakariassen KS. Flow-based assays for global assessment of hemostasis. Part 1: Biorheologic considerations. J Thromb Haemost 2006; 4: 2486-7.
9. Nitu-Whalley IC, R A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000; 86: 998-1004.
10. Lester W, Jones NL, Guilliatt A, Surdhar GK, Enayat MS, Hill FGH. A common mutation 4247 T>A (I1416N) causing type 2M von Willebrand disease in patients from three unrelated families previously diagnosed as severe type 1 VWD (abstract). J Thromb Haemost 2003; 1: P0098.
11. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-21.
12. Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Perez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 6: 762-71.
13. Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 2006; 32: 492-8.
14. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32: 485-91.
15. Preston FE. Assays for von Willebrand factor functional activity: a UK NEQAS survey. National External Quality Assessment Scheme. Thromb Haemost 1998; 80: 863.
16. Zwaginga JJ, Sakariassen KS, King MR, Diacovo TG, Grabowski EF, Nash G, Hoylaerts M, Heemskerk JW. Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1-3? J Thromb Haemost 2007; 5: 2547-9.
17. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157: 105-32.